PE-22-28: Complete Research Profile — Spadin Analog, TREK-1 Blocker, and Rapid-Onset Antidepressant Peptide for Nootropic Research (2026)

PE-22-28: Complete Research Profile — Spadin Analog, TREK-1 Blocker, and Rapid-Onset Antidepressant Peptide for Nootropic Research (2026)

PE-22-28 is a synthetic heptapeptide developed as an optimized analog of spadin — a naturally occurring peptide derived from the pro-peptide propeptin/sortilin that was identified in the early 2010s as a novel endogenous antidepressant compound. While spadin (also designated PE 12-28 for its position in the sortilin sequence) demonstrated promising TREK-1 channel-blocking and antidepressant properties, it had notable limitations: moderate receptor affinity, short in vivo half-life (~7 hours), and susceptibility to proteolytic degradation. PE-22-28 was engineered to address these limitations — retaining only the 7 amino acids essential for TREK-1 channel inhibition while dramatically increasing potency and stability.

The result is a molecule that blocks the TREK-1 two-pore domain potassium (K2P) channel with an IC50 of approximately 0.12 nM — roughly 300–500-fold more potent than spadin's IC50 of 40–60 nM — and demonstrates antidepressant-like effects in murine models within 4 days of administration, compared to the 2–4 week onset characteristic of conventional SSRIs and SNRIs. Additionally, PE-22-28 shows evidence of hippocampal neurogenesis stimulation and synaptogenesis promotion, raising interest beyond antidepressant applications into the broader domain of cognitive enhancement and nootropic research.

This profile is provided for Research Use Only (RUO). All content is for educational and scientific research purposes. PE-22-28 has not been approved for human therapeutic use.

---

Structural Identity

Common name: PE-22-28 (also written PE 22-28; sometimes called "Mini-Spadin")

Class: Synthetic heptapeptide; TREK-1 channel antagonist; spadin analog

Length: 7 amino acids

Derived from: Spadin (PE 12-28), itself derived from sortilin pro-peptide

Molecular Weight: ~800–900 Da (heptapeptide; verify by CoA)

Target: TREK-1 (TWIK-Related K⁺ Channel 1; also known as KCNK4 or K2P4.1)

IC50 at TREK-1: ~0.12 nM (vs. 40–60 nM for spadin)

Half-life advantage: Significantly extended compared to spadin (~7h); stabilized analogs (G/A-PE 22-28) reported at ~21h

The seven amino acid sequence of PE-22-28 represents the minimal active fragment of spadin capable of blocking TREK-1 with high affinity. Systematic truncation studies established that this heptapeptide retains superior TREK-1 affinity compared to the full 17-residue spadin, suggesting that the additional residues in the parent compound introduce conformational flexibility that reduces binding efficiency.

---

Background: Spadin, Sortilin, and TREK-1 Discovery

The Sortilin–Spadin Connection

Sortilin (also known as NTR3 or neurotensin receptor 3) is a type-I transmembrane receptor broadly expressed in the brain, particularly in the hippocampus and cortex. During biosynthesis, sortilin's pro-domain is cleaved to generate the mature receptor and the released pro-peptide propeptin, from which the shorter active fragment spadin (residues 12–28 of the pro-peptide) is derived. The discovery that this endogenous secreted peptide had potent antidepressant-relevant biological activity emerged from studies linking TREK-1 channel function to mood regulation.

TREK-1: The Antidepressant Target

TREK-1 is a member of the two-pore domain potassium (K2P) channel family — background potassium channels that regulate neuronal resting membrane potential and excitability. Unlike voltage-gated channels, K2P channels are constitutively active and are modulated by diverse stimuli including membrane stretch, temperature, pH, lipids (including lysophospholipids), and neurotransmitters.

The antidepressant relevance of TREK-1 was established through genetic deletion studies: TREK-1 knockout mice display a phenotype resistant to depression in multiple validated behavioral models (forced swim test, tail suspension test, learned helplessness). This "antidepressant phenotype" was linked mechanistically to enhanced serotonin, norepinephrine, and dopamine signaling in the hippocampus and prefrontal cortex — regions central to mood regulation. TREK-1 deletion also promotes hippocampal neurogenesis, consistent with the neurogenesis hypothesis of antidepressant action.

The implication is clear: inhibiting TREK-1 pharmacologically should recapitulate the antidepressant phenotype seen in TREK-1 knockout animals — a hypothesis that spadin and subsequently PE-22-28 were developed to test.

---

Mechanism of Action

TREK-1 Channel Blockade

PE-22-28 blocks the TREK-1 K2P channel by binding to the channel's extracellular domain with high affinity (IC50 ~0.12 nM). Channel blockade reduces potassium efflux, increasing neuronal membrane excitability and enhancing the firing probability of neurons in circuits relevant to mood, memory, and cognitive function. This is analogous in principle to how SSRIs increase serotonin synaptic availability — but through an entirely different mechanism acting earlier in the circuit.

Importantly, PE-22-28's specificity for TREK-1 over related K2P channels (TREK-2, TRAAK) provides relative selectivity within the channel family, though cross-reactivity profiling at higher concentrations remains important for researchers designing experiments.

Downstream Monoamine Effects

TREK-1 inhibition in key brain regions produces enhanced serotonergic, noradrenergic, and dopaminergic signaling. The TREK-1 channel is expressed on serotonin-releasing neurons in the dorsal raphe nucleus and on neurons in circuits involving the locus coeruleus (norepinephrine) and ventral tegmental area (dopamine). Reducing TREK-1-mediated hyperpolarization in these populations increases firing rates and neurotransmitter release — an effect that mirrors the downstream consequences of conventional antidepressants but through a presynaptic/neuronal excitability mechanism rather than reuptake inhibition.

Hippocampal Neurogenesis

One of the most research-compelling findings from PE-22-28 studies is stimulation of adult hippocampal neurogenesis — the generation of new neurons in the dentate gyrus of the hippocampus, a process strongly implicated in antidepressant mechanisms, memory formation, and stress resilience. PE-22-28 administration in mouse models robustly increases markers of hippocampal neurogenesis and synaptogenesis, consistent with its classification not only as an antidepressant research compound but as a potential neurogenic agent relevant to cognitive and nootropic research.

---

Preclinical Research Findings

Antidepressant Activity: Rapid Onset

The most striking finding from PE-22-28 research is its speed of action compared to conventional antidepressants. In validated murine depression models (forced swim test, novelty-suppressed feeding, chronic mild stress), PE-22-28 demonstrates significant antidepressant-like effects after 4 days of administration. Conventional SSRIs (fluoxetine, escitalopram) and SNRIs (venlafaxine) typically require 2–4 weeks to show behavioral effects in the same models — a delay that corresponds to the clinical reality of antidepressant treatment where therapeutic effects emerge over weeks.

This rapid onset is mechanistically significant. SSRIs' delayed onset is partly attributed to the time required for desensitization of autoreceptors (5-HT1A) and downstream adaptive changes. PE-22-28's TREK-1 blockade mechanism bypasses these adaptive steps by directly increasing neuronal excitability, potentially explaining the faster timeline.

Neurogenesis and Synaptogenesis Markers

Studies using BrdU/EdU incorporation and doublecortin immunostaining — standard markers for neurogenesis — show increased hippocampal neurogenesis in PE-22-28-treated animals. Dendritic spine density and synaptophysin staining indicate synaptogenesis promotion as well. These structural plasticity changes are closely associated with the antidepressant and cognitive effects observed in behavioral testing, and may be relevant to the nootropic research interest in PE-22-28.

Cognitive and Nootropic Effects

The hippocampus is central to spatial memory, episodic memory, and pattern separation. Given hippocampal neurogenesis stimulation and the cognitive roles of TREK-1 regulation, PE-22-28 has attracted interest in nootropic research beyond its antidepressant profile. Preclinical studies report improvements in hippocampus-dependent memory tasks in mouse models. The mechanistic basis — enhanced hippocampal excitability + neurogenesis — provides a biologically coherent explanation for cognitive effects distinct from simple stimulant mechanisms.

Anxiety-Related Research

Some studies have examined PE-22-28 in anxiety models. TREK-1's role in anxiogenesis means channel blockade may produce anxiolytic effects in addition to antidepressant-like activity, though the anxiety-related evidence base is less developed than the antidepressant findings. Researchers in anxiety and stress neurobiology should evaluate whether PE-22-28's profile overlaps with established anxiolytic benchmarks in their specific experimental models.

In Vivo Stability: Advantage Over Spadin

A critical practical finding is PE-22-28's improved in vivo stability relative to spadin. Spadin's ~7-hour half-life limits experimental utility. PE-22-28 (and particularly its stabilized analogs G/A-PE 22-28 and biotin-G/A-PE 22-28) demonstrates significantly extended duration — up to 21–23 hours — improving the feasibility of once-daily dosing protocols in animal studies and reducing the complexity of multi-dose experimental designs.

---

PE-22-28 vs. Spadin vs. Conventional Antidepressants

---

Research Applications

PE-22-28 is appropriate for the following research contexts:

• •Depression and mood disorder models — studying rapid-onset antidepressant mechanisms, comparing TREK-1 channel blockade to SSRI/SNRI mechanisms in standard behavioral paradigms
• •K2P channel pharmacology — characterizing TREK-1 channel function, selectivity within K2P family members, and the neurobiology of K2P channels in mood and cognition circuits
• •Hippocampal neurogenesis research — using PE-22-28 as a pharmacological tool to stimulate neurogenesis and study its downstream behavioral and structural consequences
• •Nootropic mechanism research — investigating peptide-based cognitive enhancement through neuroplasticity mechanisms distinct from cholinergic, dopaminergic, or glutamatergic nootropic approaches
• •Rapid-onset antidepressant pharmacology — understanding what drives the 4-day vs. 2–4-week onset differential compared to conventional antidepressants
• •Anxiety and stress neurobiology — evaluating TREK-1 channel contributions to anxiety phenotypes in stress models
• •Comparative neuroplasticity studies — PE-22-28 alongside established neurogenic agents (e.g., ketamine, BDNF agonists, BPC-157) for multi-mechanism neuroplasticity research

---

Important Research Considerations

Peptide delivery in CNS research: PE-22-28 is a heptapeptide. While smaller than many research peptides, CNS delivery via peripheral administration faces blood-brain barrier challenges. Published preclinical studies use peripheral administration routes with confirmed CNS behavioral effects, but researchers should validate CNS exposure in their model systems.

Selectivity profiling: TREK-1 is one of 15+ human K2P channels. At higher concentrations, cross-reactivity with related channels (TREK-2, TRAAK) becomes possible. Use functional selectivity profiling when investigating TREK-1-specific vs. K2P-class effects.

Preclinical-only evidence base: All published PE-22-28 research is in rodent models. No human clinical data exists. The translation of rodent TREK-1 pharmacology to human neurobiology involves additional uncertainties that researchers should acknowledge in their interpretation and experimental design.

Stability in assay conditions: Heptapeptides can be subject to rapid proteolysis in serum-containing media. Test stability in your specific assay conditions and consider stabilized analogs (G/A-PE 22-28) for applications requiring extended exposure windows.

---

Quality Standards and Sourcing

• •HPLC purity: ≥95% minimum for research-grade material
• •MS confirmation: Verify molecular weight matches the 7-residue sequence; deletion peptides from incomplete synthesis can be biologically active and confound results
• •Endotoxin testing: Essential for neuronal culture assays where LPS is highly cytotoxic and confounds readouts
• •Sequence verification: Request CoA with sequence confirmation
• •Storage: Lyophilized form stable at -20°C; reconstituted in sterile water, PBS, or saline; typical working concentrations in cell-based assays: 0.1–100 nM

---

Storage and Handling

• •Lyophilized: -20°C long-term; protect from moisture
• •Reconstituted: 4°C for up to 2 weeks; -80°C for long-term storage; avoid repeated freeze-thaw cycles
• •Solubility: Good aqueous solubility expected for short peptide; verify in your specific buffer conditions
• •Working concentration: 0.1–100 nM typical range based on published in vitro studies

---

Key References

• •Djillani A et al. (2017). Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol 8:643. PMC5601071
• •Mazella J et al. (2010). Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol 8(4):e1000355.
• •Borsotto M et al. (2018). Fighting against depression with TREK-1 blockers: Past and future — A focus on spadin. Pharmacol Ther 194:185–198. ScienceDirect
• •Djillani A et al. (2019). Role of TREK-1 in Health and Disease, Focus on the Central Nervous System. Front Pharmacol 10:379.
• •Heurteaux C et al. (2006). Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 9(9):1134–41.

---

Further Reading:

• •P21 (P021): CNTF-Derived Peptide for Neurogenesis and Memory Research
• •PYY (Peptide YY): Complete Research Profile — The Gut Satiety Hormone in Appetite Regulation and Obesity Research (2026)
• •PNC-27: Complete Research Profile — p53-Derived Anticancer Peptide and Selective Cancer Cell Lysis via Poptosis (2026)
• •Adipotide (FTPP): Complete Research Profile — Prohibitin-Targeting Proapoptotic Peptide for Adipose Vasculature Research
• •Reconstitution Calculator
• •Peptide Stack Builder

---

This article is for educational and scientific research purposes only. PE-22-28 is a research compound not approved for human therapeutic use. Nothing in this profile constitutes medical advice.